Biomaterials’ Role in Improving Patient Care from Drug Testing and Delivery to Theragnostics and Regenerative Medicine Authors: Sabina Cristiana Badulescu, Emma Adriana Ozon, Adina Magdalena Musuc, Manuela Diana Ene, Rica Boscencu Published: 2026 ABSTRACT Over the past 200 years (1820–2020), global life expectancy has nearly tripled, increasing from 26 to 72.91 years, due to factors such as poverty reduction and public health initiatives. Today, society faces different challenges than it did centuries ago. In patient care and healthcare system priorities, the goal is to develop smart, feasible, long-lasting, cost-effective, readily available, adverse-reaction-free, adaptable, and personalized solutions that minimize patient discomfort, reduce caregiver effort, and decrease hospitalization duration and costs. In this context, biomaterials serve as versatile tools capable of performing a wide range of diagnostic, therapeutic, and theragnostic functions. Thanks to their biocompatibility, biodegradability, surface chemistry, and responsiveness, biomaterials are currently addressing issues such as patient compliance (through controlled drug-delivery systems and smart wound dressings), long transplant waiting lists, transplant rejection, non-adaptable prosthetics (artificial organs), oncology treatment efficacy (nano-formulations for theragnostics and multiple tumor targeting), and inconsistent in vitro drug-testing models (organs-on-a-chip). In this review, we focus on biomaterials’ smartness, then explore databases for efficient product design, and finally highlight their applications in the biomedical field, especially in drug delivery, tissue engineering, and regenerative medicine. 1. Introduction Over the past two centuries, humanity has optimized several life parameters in its favor: living standards, education, and economy, as well as public health and patient care (including clean water, nutrition, sanitation, antibiotics, vaccines, medicines for chronic and rare diseases, technologies for new drug design, and methods for improving patient conditions, such as neonatal, geriatric, or personalized healthcare). This progress has led to an almost threefold increase in life expectancy [1]. A longer life means the human body must be supported for endurance rather than a sprint. In today’s more sedentary, mentally stressed, and aging society (by 2030, one in six people worldwide is expected to be over 60, and by 2050, this age group is projected to reach 22% [2]), with approximately 17% of the global population being smokers [3,4] and 16% obese [5], thus at risk of developing cardiovascular, pulmonary, and/or musculoskeletal conditions. One in three people lives with multiple chronic conditions [6,7], about one in five develops cancer in their lifetime [8], and 2% experience chronic wounds, including difficult-to-heal injuries [6,9]. There is a pressing need for smart, long-term, cost-efficient, feasible, and effective medical solutions that maximize patient benefit regardless of age (from newborn to elderly), support caregivers—preventing them from becoming patients due to the strain of caregiving—and enable the medical system to provide simple, durable, and adaptable yet personalized solutions. To meet this need, several directions can and have already been addressed to some extent, including: designing smart products for rapid and non-invasive diagnostics and self-monitoring (biosensors); creating medicines and medical devices that require less frequent administration or replacement and can maintain a constant plasma or local drug concentration with minimal adverse reactions (improving patient compliance); combining treatment and diagnostics within the same method or product (reducing costs); offering grafts, prosthetics, and artificial organs that integrate seamlessly and adapt with the recipient’s body, eliminating the need for transplants or the risk of rejection; and building more accurate in vitro drug-testing platforms to minimize the preclinical trial phase of new drugs. All these solutions share several key features: they are intended not to disturb the body’s homeostasis, to mimic human tissue characteristics and aid regeneration, and to be as biocompatible and targeted in their action as possible. To achieve these goals, the materials used in these medical products must closely resemble our own cellular and tissue microenvironment. The only class of materials that possesses these characteristics, apart from our own body’s molecules and cells, is biomaterials. 2. Methodology This study’s design involved three main steps: Advanced search in the Web of Science Core Collection databaseThe main objective of this step was to establish a core framework for the study’s direction. A secondary objective was to identify research trends in biomaterials (related to tissue engineering, regenerative medicine, personalized medicine, drug testing and delivery, and theragnostics), as well as potential research gaps. Advanced search in the Web of Science Core Collection database The main objective of this step was to establish a core framework for the study’s direction. A secondary objective was to identify research trends in biomaterials (related to tissue engineering, regenerative medicine, personalized medicine, drug testing and delivery, and theragnostics), as well as potential research gaps. Search in other databases and web pages for in-depth, explanatory, and complementary informationThe purpose of this step was to supplement the framework from step 1 with relevant information and to address the identified research gaps. Search in other databases and web pages for in-depth, explanatory, and complementary information The purpose of this step was to supplement the framework from step 1 with relevant information and to address the identified research gaps. Integration and new outputThe focus of this step was to generate original content that researchers can use as a tool, featuring an easy-to-use interface. Integration and new output The focus of this step was to generate original content that researchers can use as a tool, featuring an easy-to-use interface. Advanced search in the Web of Science Core Collection database Advanced search in the Web of Science Core Collection database The advanced search of the literature was performed in the first step using a unique database: Web of Science Core Collection (WoS), which was accessed through the E-nformation platform—login via an institutional profile (https://www.e-nformation.ro/profil-acces, accessed on 10 January 2026) in order to have access to the Advanced Search menu option from WoS. In the Advanced Search tab, the Query Builder was used for all the searches, because it offers complete control over the syntax that is built (keywords, operators, filters), and it saves any generated result as a new “set” (a set of bibliographic results) at the bottom of the page. This function allows us to easily compare the results (bibliographic sets) that we obtain based on the query and further refine our search. We performed our study in “All Editions” of the Web of Science Core Collection database, and adopted a search based on topic (TS), which means that the query is applied in the following metadata: title, abstract, and document keywords, which we found relevant enough. We used the star symbol (*) after individual keywords or syntagms used in the query, because this way we ensured that all similar terms, spellings, and forms of the word, differing by any number of characters from ours, were included (e.g., biomaterial* = biomaterial, biomaterials, bio-material, bio-materials, etc.). We used different queries until we were satisfied with the following one: TS = (biomaterial* and (tissue engineering OR TE or regenerative medicine* OR RM OR TERM OR personalized medicine* OR drug test* OR drug delivery* OR theragnostics* OR bioprint* OR 3D print* OR 4D print*)), which initially generated 52,580 results. Through this syntax, we wanted to identify all bibliographic resources that contained in the previously mentioned metadata the keyword biomaterial(s) AND at least one of the other keywords separated through the “OR” operator (theragnostics, drug delivery, regenerative medicine, bioprint, etc.) because we were interested in the relationship between biomaterials and these terms and how the niches created by the combination of these fields interpenetrate. We also added the abbreviations TE (tissue engineering), RM (regenerative medicine), and TERM (tissue engineering regenerative medicine) to the search syntax because they are sometimes found in the abstract, even if the title or keywords selected by the authors do not include these terms in extenso. After applying a publication date range filter for a custom period (1 January 2021 to 31 December 2025, the last five complete years), the obtained database contained 21,611 results. We refined this by including only review articles (filtered by document type), which resulted in 7251 results. Further inclusion criteria were applied: highly cited papers (326 results)/hot papers (13 results)/highly cited and hot papers (11 results). It is important to know that:Highly cited papers represent those articles that rank in the top 1% of citations for their specific field and publication year. Citations are compared within 22 specific research fields and against papers published in the same year, adjusting for differences in citation habits. Only papers published in the last 10 years are considered.Hot papers represent those articles that receive a large number of citations soon after publication, relative to other papers of the same field and age. They are papers published in the past two years that received a number of citations in the most recent two-month period, placing them in the top 0.1% of papers in the same field. Highly cited papers represent those articles that rank in the top 1% of citations for their specific field and publication year. Citations are compared within 22 specific research fields and against papers published in the same year, adjusting for differences in citation habits. Only papers published in the last 10 years are considered. Highly cited papers represent those articles that rank in the top 1% of citations for their specific field and publication year. Citations are compared within 22 specific research fields and against papers published in the same year, adjusting for differences in citation habits. Only papers published in the last 10 years are considered. Hot papers represent those articles that receive a large number of citations soon after publication, relative to other papers of the same field and age. They are papers published in the past two years that received a number of citations in the most recent two-month period, placing them in the top 0.1% of papers in the same field. Hot papers represent those articles that receive a large number of citations soon after publication, relative to other papers of the same field and age. They are papers published in the past two years that received a number of citations in the most recent two-month period, placing them in the top 0.1% of papers in the same field. The last inclusion criteria or filter applied (highly cited and hot papers) generated our core-frame bibliographic selection (Supplementary Figure S1). The step-by-step process of this advanced search can be followed in the diagram presented in Figure 1. All the databases were downloaded both as Excel and plain text files, using the Full Record option in terms of metadata and the “Records from 1 to … (last item)” option to download every entry; for Db7251, eight files were downloaded for each extension, since one file can contain a maximum of 1000 items. The Excel files were used to identify the publication names and authors, but no further refinement was carried out with them. The plain text files were used for analysis in the VOSviewer software. Although the core database (11 highly cited and hot review papers published between 2021 and 2025—Table S1, Supplementary Materials) offered us a picture of the present-day main research and funding directions, the last three databases obtained after each inclusion criterion (filter) were analyzed in order to obtain a clearer view of the existing studies over collateral research trends, and especially over potential research gaps. First of all, a general preview was obtained using the “Analyze results” and “Citation report” functions in the Web of Science platform for each of the above-mentioned generated databases, which we define as: Db7251, Db326, and Db11. Using the “Analyze results” functionality, we obtained 3 bar-charts and, respectively, 3 tree-map charts that show the top 10 WoS Categories (specific fields of study) that the included papers in each database are subscribed to. The functionality allows selection between 5, 10, 15, 20, and 25 results per chart/map, but we considered that 10 items are sufficiently relevant and easy to visualize. These graphs can be found in Supplementary Materials (Figures S2–S7). For better integration of these data, we designed Table 1, which presents the dynamics of these granulated research areas (WoS categories) between the 3 databases. It is obvious that the narrower the search, the more niche and more expensive domains (Nanoscience, Polymer Science, Cell Biology) are included or assigned higher ranks, while other more general areas disappear (Physics Applied, Material Science Multidisciplinary, Pharmacology Pharmacy) or are assigned a lower position in the hierarchy (Material Science Biomaterials). These observations indicate that there are probably notable relevant results in niche domains regarding our search that we should investigate further than Db11, but also which broad and narrow academic fields are connected to the study of biomaterials. The “Citation report” functionality shows, simultaneously, the evolution of scientific production and that of the citation index in the selected time interval (2021–2025) for the three databases. As one can infer from Figure 2, Figure 3 and Figure 4, the scientific production in the biomaterials field grew significantly in 2025 compared to the 2021–2024 period (Figure 2), and since the same cannot be observed for reviews (Figure 3), this could mean that this was a prolific time interval for experimentation with biomaterials in the scientific world, which could mean that many advancements were made in obtaining viable applications. The graph for Db11 (Figure 4) does not offer much information, except for the fact that until 2024, it appears that there were not too many highly cited papers in this domain, which gives us a starting point of relevant, probably applicable, scalable, or translational results bursting into the biomaterials field. In the last part of this bibliometric study, we used the VOSviewer software (version 1.6.20) to generate keyword co-occurrence maps for each of the three databases. The first attempts to obtain such bibliometric maps led us to an intermediate curation step that involved generating a thesaurus file in order to avoid duplicates (different spellings, singular–plural forms, synonyms, or syntagms with the same meaning, e.g., nanotechnology–nanoparticles–nanotubes–graphene oxide–nanofibers–nanocarriers = nano). Each map was generated by selecting the following options from the VOSviewer software:Create a map based on bibliographic data.Read data from bibliographic database files.Select the .txt files with the database, downloaded from WoS.Apply the thesaurus file.Apply a threshold (minimum number of occurrences of a keyword in the files from the respective database).Determine whether or not to keep all the keywords that meet the threshold. Create a map based on bibliographic data. Create a map based on bibliographic data. Read data from bibliographic database files. Read data from bibliographic database files. Select the .txt files with the database, downloaded from WoS. Select the .txt files with the database, downloaded from WoS. Apply the thesaurus file. Apply the thesaurus file. Apply a threshold (minimum number of occurrences of a keyword in the files from the respective database). Apply a threshold (minimum number of occurrences of a keyword in the files from the respective database). Determine whether or not to keep all the keywords that meet the threshold. Determine whether or not to keep all the keywords that meet the threshold. We present below the obtained co-occurrence bibliometric maps, which were quintessential in determining what points the present review should address in order to cover some gaps or under-discussed subjects in the chosen field of research. For the 7251 publications in the database, the keyword co-occurrence threshold was set to 138, because we aimed to have a maximum of 50 keywords in each map for better visualization and interpretation. Using the 138 threshold in this case, out of 23,479 keywords, exactly 50 met the co-occurrence threshold. This setting generated a network map with 50 items grouped in 3 clusters with 1193 links (Figure 5). The automated view was rotated 180° for better visualization. Cluster 1 (red) in the below network map contains 22 items revolving around the drug-delivery, stem cells, and nano concepts, so it is consistent with the biomedical–pharmaceutical direction. Cluster 2 (green) contains 16 items referring mostly to scaffolds, materials, material properties, and technologies, so it is an engineering-oriented cluster. Cluster 3 (blue) contains 12 items focused on hydrogels, natural polymers, and regeneration, so it is a bridge between a chemical and a biological approach to the subject, which is consistent with its position between Cluster 1 (biology-oriented) and Cluster 2 (chemical engineering-oriented). The network map is useful for observing the connections between different items (keywords) and the strength of their link. The same settings also generated an overlay map (not presented) and 2 density maps: one for items and one for clusters (both presented below—Figure 6 and Figure 7). These density maps are useful to observe the proportionality of occurrence between the terms (the more intense, the higher the occurrence of the keyword in the item density map) and the distribution of the clusters (how much a certain cluster takes up in the entire map, which indicates which field of study is addressed more and which one is still in its infancy). Figure 6 shows that tissue engineering, drug delivery, nanotechnologies, scaffolds, stem cells, and hydrogels are quite common subjects in the selected literature, whereas bioprinting, cancer, therapy, regenerative medicine, and other related subjects are not as developed. Figure 7 allows us to observe that the biological approach has the biggest proportion, followed by the engineering one, and that intersecting domains like tissue regeneration–regenerative medicine are just beginning to emerge. It is interesting to see how the term “chitosan”, although integrated into the third cluster by its links, is positioned inside the second cluster, showing how a certain concept can cross the barrier of one particular domain. Similar maps were generated for Db326 and for Db11 and are presented below. For consistency, all maps were generated using the same thesaurus file, and in each case, we aimed to include a maximum of 50 keywords for better visualization and to facilitate the comparison process between the same type of map generated for different databases. For the Db326 network map (Figure 8), the co-occurrence threshold was set to 8, thus obtaining 46 items that met this condition, out of 2276 identified keywords. The 46 items are grouped in 5 clusters and present 730 links. It appears that, as the database becomes more restricted (filtered), more specific keywords appear, and thus more clusters define niche subjects connected to the central theme. Cluster 1 (red) contains 16 items and is focused, as in the case of Cluster 1 from Db7251, on drug delivery and nanotechnology. However, what is different from the first database here is that this cluster refers to more advanced concepts, such as wound healing, cancer, injectable hydrogels, and mechanisms (so it is an in-depth approach compared to Cluster 1—Db7251). Cluster 2 (green) contains 15 items grouped around scaffolds, in vitro, tissue, and bone regeneration, so it maintains the engineering approach, but it also brings in biomedical applications, compared to Cluster 2 from Db7251. Cluster 3 (blue) contains 8 items referring to materials and their properties, and it definitely creates a material/chemical-oriented bridge between Cluster 1 and Cluster 2. Cluster 4 (yellow) contains 4 quite dispersed items that cross over into the biological approach: cells, biocompatibility, regenerative medicine, and in vivo. Cluster 5 (purple) contains only 3 items: stem cells, extracellular matrix (ECM), and growth factors, and it seems to be a very specific subsection of the large biomaterials domain, connecting (by its position) all the above clusters of Db326. The item density and the cluster density co-occurrence maps for Db326 show, respectively, a tissue-engineering–bone regeneration–drug-delivery–nano focus (Figure 9) and the fact that the emerging research trend seems to be directed towards regenerative medicine and in-depth biological studies of biomaterials connecting engineering and cell biology techniques (Figure 10). Last but not least, the keyword co-occurrence bibliometric maps for Db11 indicate the terms that keep occurring even in extremely niche searches regarding the biomaterials’ domain, including drug delivery, nano, polymers, hydrogels, and in vitro (the terms were enumerated from the highest to the lowest occurrence based on the item density map—Figure 11). The connections that link these items can be observed in Figure 12. For Db11, the co-occurrence threshold was 3 (default), and out of 112 identified keywords, only 5 met the condition, generating only one cluster, which is why the item density and the cluster density maps look the same (we present only the item density map). Summarizing the above bibliometric study, one can identify well-developed academic research areas in the biomaterials field, such as nanotechnology, hydrogels and polymers, stem cells, scaffolds, drug delivery, in vitro studies, and bone regeneration, but also insufficiently addressed areas, such as regenerative medicine and the emerging TERM domain, theragnostics, regeneration of other tissues besides the bone system, wound healing and wound dressing (in relation to biomaterials), cancer, drug testing, therapies and personalized medicine, drug delivery in relation to the cellular microenvironment, tissue engineering components, and bio-fabrication technologies, as well as in-depth biological approaches to the above-mentioned fields. This distinction represents the conceptual foundation upon which the present analysis aims to systematically and coherently highlight the less visible scientific reference points that underpin the field of biomaterials. The methodological approach involved organizing relevant information into analytical categories, critically evaluating the specialized literature, and integrating the findings into an interpretive framework that facilitates a deeper understanding of the mechanisms and principles governing the development and application of biomaterials. 2.Search in other databases and web pages for in-depth, explanatory, and complementary information Search in other databases and web pages for in-depth, explanatory, and complementary information As we present in the PRISMA flow diagram below (Figure 13), for an in-depth approach and to shed light upon topics insufficiently developed in the bibliometric study of selected literature, we conducted an extensive search in databases other than WoS (PubMed, Elsevier, etc.) and in other electronic resources, such as research or health organizations’ web pages, product brochures from companies in the field, original data articles and other review articles in the biomaterials domain, and reports from market research companies that address our proposed subject. The number of identified, screened, and included studies based on specific criteria, both from the WoS database and outside of it, can be observed in the diagram; for studies from WoS, the inclusion criteria were presented previously in this chapter, and no other exclusion criteria were applied, whereas for studies outside the WoS database, exclusion criteria were applied, since the search was very specific. Wikipedia as a source and also duplicates of web pages reached from different searches were excluded. Overall, 220 bibliographic resources were used (included) in the present review: 11 from the WoS-generated bibliographic database and 209 from other specific searches. 3.Integration and new output Integration and new output The main goal of this research was to generate a material that can be used as a research tool. Therefore, by integrating the previously mentioned studies, we generated comprehensive tables in which any researcher, whether now approaching the field of biomaterials for the first time or already having extensive experience, can find categorized and filterable information to use either as an answer to targeted questions or as a starting point for other studies or comparisons. In addition, the chapters that we have defined emphasize the identified research gaps, trying to extract as much information as possible from the existing literature on these less addressed topics. 3. Biomaterials and Computational Material Science Databases In the process of using biopolymers for various biomedical applications, the first step is to identify the optimal molecules. Searching for and comparing the different properties of these materials, either virtually or in the laboratory, is a challenge. In recent years, databases with biomaterials have been developed, which are summarized in Table 2 and detailed in the Supplementary Materials (Table S1). All the included databases are currently active (2026), and for each, it is indicated whether artificial intelligence (AI) or machine learning (ML) have been integrated into its design. The databases provide comprehensive and detailed collections of properties for a wide variety of polymers, both natural and synthetic. Typical applications and processing grades for each main polymer are easily accessible, making the databases valuable tools for researchers in both small laboratories and industry. More complex structures, such as multilayer films, nanomaterials, electro-optical, and electronic devices, are being developed in contemporary polymer science and engineering. These architectures require more advanced testing to evaluate end-use performance. Additionally, researchers can use the available databases to design and customize polymers and complex polymeric structures to satisfy certain end-use performance requirements by modulating the structure–property interactions of polymeric materials. In addition to databases with ready-to-use materials, such as those mentioned above, the digital era also provides platforms for computational simulation of materials, in silico development, and digital testing in virtual environments that simulate, at the molecular level, the thermodynamic conditions and chemical interactions of real environments. These platforms (examples are listed in Table 3—all currently active) are emerging products of computational chemistry and computational materials science. They now serve as essential tools for developing advanced materials with product-targeted properties, for drug discovery and drug design, and for education. The benefit of dynamic visualization tools is that they make it easy to obtain various significant analyses from the prospective data. This facilitates the exploration and exploitation of opportunities for innovation and knowledge management, as well as the appropriate communication of analyzed information to researchers. 4. Important Applications of Biomaterials in Modern Medicine—Smart Products for Diagnostics, Treatment, and Theragnostics Biomaterials have proven to be highly valuable not only in diagnostic platforms—such as biosensors designed to detect and quantify specific analytes, including those used in blood glucose monitoring devices—but also in therapeutic and theragnostic applications addressing a broad spectrum of clinical conditions, including post-traumatic tissue loss defects, complex post-surgical reconstructions, and tissue damage resulting from severe infections or necrosis. 4.1. Wound Dressings Wound healing is a complex, dynamic process that researchers and clinicians worldwide strive to control as effectively as possible to prevent the consequences of interruption or cessation at any stage, which can result in loss of life or severely diminished quality of life. Skin diseases affect several million people globally, with 1–2% in developed countries suffering from chronic wounds that are difficult to heal. Currently, there are about 3000 wound care products available. Conventional dressings (bandages, gauze) are not effective for healing complex wounds (such as extensive burns, diabetic foot ulcers, or infected wounds), which is why new solutions are being developed. These new approaches combine biomaterials (biopolymers), bioactive molecules, and cells within the framework of skin tissue engineering [46,47]. These solutions can be broadly classified as acellular or cellular (allogeneic or autologous) skin substitutes, each further categorized as temporary (removable), temporary (biodegradable, bioresorbable), or permanent (integrating graft). Supplementary Material Table S3 presents a list of such products, already marketed or in clinical trials worldwide. This table was inspired by Boyce et al. [48] and Snyder et al. [49]. Acellular scaffolds can also be combined with both allogeneic and autologous cells, with the latter combination being the most effective. Regarding the acellular skin substitutes, there are also others worth mentioning:Smart dressing for the treatment of chronic diabetic ulcers (Figure 14a): it provides oxygen and trophic biochemical factors to blood vessels while monitoring healing. This is a theragnostic solution because it combines treatment with healing monitoring. By combining electronics, wound healing, microfabrication, biomaterials, and drug delivery, the dressing integrates sensors and actuators in close contact with the skin [50,51,52].Dissolvable dressing for burn treatment (Figure 14b): a self-dissolving hydrogel dressing that provides a barrier against infections and promotes healing, preventing tissue trauma caused by repeated removal of traditional dressings. As it dissolves into safe by-products in a controlled manner, the hydrogel allows the dressing to be removed on demand and the wound to be re-exposed without mechanical debridement or cutting, resulting in easier and less traumatic treatment [50,53,54]. Smart dressing for the treatment of chronic diabetic ulcers (Figure 14a): it provides oxygen and trophic biochemical factors to blood vessels while monitoring healing. This is a theragnostic solution because it combines treatment with healing monitoring. By combining electronics, wound healing, microfabrication, biomaterials, and drug delivery, the dressing integrates sensors and actuators in close contact with the skin [50,51,52]. Smart dressing for the treatment of chronic diabetic ulcers (Figure 14a): it provides oxygen and trophic biochemical factors to blood vessels while monitoring healing. This is a theragnostic solution because it combines treatment with healing monitoring. By combining electronics, wound healing, microfabrication, biomaterials, and drug delivery, the dressing integrates sensors and actuators in close contact with the skin [50,51,52]. Dissolvable dressing for burn treatment (Figure 14b): a self-dissolving hydrogel dressing that provides a barrier against infections and promotes healing, preventing tissue trauma caused by repeated removal of traditional dressings. As it dissolves into safe by-products in a controlled manner, the hydrogel allows the dressing to be removed on demand and the wound to be re-exposed without mechanical debridement or cutting, resulting in easier and less traumatic treatment [50,53,54]. Dissolvable dressing for burn treatment (Figure 14b): a self-dissolving hydrogel dressing that provides a barrier against infections and promotes healing, preventing tissue trauma caused by repeated removal of traditional dressings. As it dissolves into safe by-products in a controlled manner, the hydrogel allows the dressing to be removed on demand and the wound to be re-exposed without mechanical debridement or cutting, resulting in easier and less traumatic treatment [50,53,54]. As can be observed, recent advances in biomaterials have profoundly transformed the management of acute and chronic wounds, offering increasingly sophisticated solutions that overcome the limitations of traditional dressings. Bioactive materials, smart hydrogels, nanostructures, and skin substitutes provide not only mechanical protection but also targeted therapeutic interventions, stimulation of tissue regeneration, and continuous monitoring of the healing process. The integration of advanced technologies such as flexible microelectronics, controlled-release nanocarriers, and stimuli-responsive biomaterials opens new directions for designing biomaterials with superior biocompatibility, biodegradability, and intelligence, capable of dynamically interacting with the wound microenvironment and providing truly personalized solutions in regenerative medicine. Although these developments are remarkable, the specialized literature emphasizes the need for robust clinical studies, standardized protocols, and optimized production costs to facilitate large-scale adoption. These innovations promise to reduce complications, shorten healing times, and improve the quality of life for patients with complex wounds. 4.2. Nanocarriers and Other Solutions for Theragnostics In simplified terms, theragnostics refers to the use of a single, selective method to detect, monitor, and treat a condition [55]. In its modern definition, theragnostics is a medical approach that combines, in the same system, diagnostic capability (imaging), targeted and selective therapeutic delivery, monitoring of the therapeutic response (imaging) [56,57], and assessment of the biodistribution of the therapeutic agent (imaging), as illustrated in Figure 15. This concept was first developed in nuclear medicine [58], when an isotope of iodine was used both to detect thyroid cancer (iodine accumulates in thyroid tissue through normal metabolic processes) and to destroy cancer cells through irradiation. Since then, theragnostics has evolved into complex platforms based on specific ligands that serve as therapeutic targets (for example, iodine: radioactive iodine can be monitored through imaging by NMR), activatable contrast agents that release therapeutic agents in response to a stimulus (such as ultrasound), monoclonal antibodies conjugated with superparamagnetic iron oxide nanoparticles, and other nanostructures capable of transporting and releasing therapeutic agents in a controlled manner. In these systems, the imaging molecule and the therapeutic agent act synergistically: the antibody ensures specificity (specific binding at the site of action), while the nanoparticle serves as both a carrier of the active substance and as a tracer for magnetic imaging, enabling real-time monitoring of therapeutic efficacy. Imaging techniques used in nuclear medicine for theragnostic applications include nuclear magnetic resonance (NMR), positron emission tomography (PET), and single-photon emission computed tomography (SPECT). Recent advances have expanded theragnostics beyond nuclear imaging to include photoacoustic and optical imaging [56]. In dermatology, for example, theragnostics involves the use of substances with specific binding to precancerous or cancerous cells and monitoring of the affected area using visible light upon UV illumination (photodynamic therapy) [59]. Optical imaging offers notable advantages: high sensitivity, real-time application, low cost, and safety due to the absence of ionizing radiation [60]. The defining feature of theragnostics is the targeted delivery of the therapeutic agent–imaging molecule combination. When a carrier vehicle is needed, this may be a nanoparticle (polymeric, silica, or metal), micelle, liposome, or carbon nanotube, typically surface-modified for specific binding. Theragnostics has proven effective in treating thyroid cancer and neuroblastoma, and in addition to oncology, it is now used in cardiovascular diseases, immunotherapy, neurology, and gene therapy. Co-delivery of diagnostic and therapeutic agents within a single system enables real-time validation of therapy through continuous, non-invasive monitoring [61,62,63,64,65,66,67,68]. This allows clinicians to rapidly assess treatment efficacy at the molecular or cellular level and adjust therapeutic strategies without waiting for a macroscopic effect, such as tumor shrinkage [60]. Molecular probes and nanoparticles used in cancer imaging and molecular therapy are relevant examples of theragnostic products incorporating biopolymers [50], and the diversity of carriers, therapeutic strategies, and diagnostic methods is summarized in Figure 16. Overall, as shown in Figure 16, nanotheragnostics is one of the most promising directions in modern medicine because it integrates diagnosis, treatment, and monitoring into a single functional framework. The evolution from early applications in nuclear medicine to current platforms based on nanotechnology, advanced imaging, and targeted delivery demonstrates the remarkable potential of this approach to transform medicine into a more predictive, efficient, and patient-centered field. Therefore, theragnostics is a key step toward truly personalized medicine and the optimization of therapeutic outcomes in numerous pathologies. 4.3. Tissue Engineering (TE) The most evident role of biomaterials in tissue engineering is to provide an architectural framework similar to the extracellular matrix (ECM) to promote cell growth and tissue regeneration. They generate the porous scaffold where the cells are seeded. Therefore, biomaterials must be able to deliver populations of cells and therapeutic agents, provide a structural scaffold with optimal mechanical properties for the tissue, present a (bio)degradation rate as similar as possible (ideally, identical) to the new tissue formation rate, and adapt to the growth and development of the surrounding tissue [70]. In turn, tissue engineering finds its applicability in regenerative medicine and in personalized medicine (the two specialties sometimes overlap), in the development of smart biomaterials, in creating drug formulations with targeted delivery and/or controlled or sustained release, in building reliable solutions for in vitro drug testing, and in manufacturing high-complexity wound healing products. The applications of biomaterials and tissue engineering overlap, support, and determine each other, as can be inferred from the graphical abstract. To obtain products representing TE applications, various strategies are used, based either on cell therapies, on support scaffolds that mimic the extracellular matrix (ECM) or the tissue’s microenvironment—the extracellular fluid (ECF)—or on a combination of the two. These strategies can be used for the design and production of therapeutic products in vitro for subsequent transplantation, or for their generation in situ, directly in the body (in vivo). The manufacturing of these products is accomplished either through a bottom-up or a top-down approach, depending on the destination of the therapy and the technological, financial, and know-how resources. During the last few decades, tissue engineering has revealed positive results in solving regenerative, functional recovery, and treatment problems for most systems and organs. Since biomolecules, cells, tissues, organs, and the entire human body have complex structures capable of storing and transmitting information (DNA, RNA) and performing fine, carefully tuned functions based on feedback and biochemical communication both locally and at a distance, it goes without saying that a simple artificial prosthesis cannot fully and accurately replicate the abilities of the replaced part. Therefore, fabricating a precise substitute requires incorporating, as much as possible, all the relevant natural elements into its manufacturing. Consequently, our ability to integrate not only the macro-components (cells, matrix, signaling molecules) but also the structural and informational cellular microenvironment (micro-and nano-topography, sensitivity to physical and chemical stimuli, the combination of vascularization and multi-stratified tissue, and allographic gene expression) is crucial for a successful product [71,72]. This accurate integration is the current goal in the field of tissue engineering. However, this field serves as an umbrella that unifies the technical skills developed by researchers in many other disciplines. Advances in micro- and nanofabrication, as well as in genetic engineering techniques, contribute extensively to the development of TE products that integrate and evolve much more naturally with host tissue than traditional prostheses. The tissues and renewable organs developed so far in this field include skin, bone, periodontal tissue, cartilage, trachea, blood vessels (arteries, capillaries), cardiac tissue, nervous tissue, endocrine tissue, lung tissue, liver, pancreas, and limbal epithelium (eyes) [70,73,74,75]. For the success of these products, collaboration among specialists in related fields is essential. The domains that tissue engineering integrates are engineering and bioengineering, materials science, digital technology, chemistry, molecular biology and cell biology, medicine, and genetics [73,75]. The defining characteristics of the TE field are precision, personalization (individual-specific results), responsiveness, effectiveness, innovation, interdisciplinarity, integration of science with technology, resilience, and researchers’ creativity [73]. The fundamental elements necessary for the fabrication of tissues by tissue engineering are summarized below and schematically represented in Figure 17: i.Cells: from cell banks or patient-derived; ii.Scaffolds: for directing cell multiplication and organization (generally made of biopolymers);iii.Biomolecules: growth factors, genetic reprogramming factors (including their delivery systems) [70,75,76]. i.Cells: from cell banks or patient-derived; Cells: from cell banks or patient-derived; ii.Scaffolds: for directing cell multiplication and organization (generally made of biopolymers); Scaffolds: for directing cell multiplication and organization (generally made of biopolymers); iii.Biomolecules: growth factors, genetic reprogramming factors (including their delivery systems) [70,75,76]. Biomolecules: growth factors, genetic reprogramming factors (including their delivery systems) [70,75,76]. The concept of tissue engineering has emerged in response to the challenges faced by modern global medicine: the inability to fully replicate the functions of natural organs, the inefficiency in controlling the progression of tissue damage when using mechanical devices (prostheses) in surgical reconstruction, the incompatibility and lack of adaptability of traditional prostheses to changes in the human body (such as growth and aging), the shortage of organs and tissues needed for transplants [75,77], transplant rejection due to immunological incompatibility, and the absence of previous solutions for irreparably damaged tissues for which traditional transplantation is not an option [73]. Driven by these urgent needs, the required solutions are, in start-up terminology, “pain-killers” (must-have) rather than merely “vitamins” (nice-to-have). The field has developed continuously, keeping pace with societal advancements and even anticipating future needs. Currently, the solutions offered address both research and industrial sectors, with a particular focus on biomedical applications, as shown in Figure 18. These solutions encompass both types of products and services mentioned above: those that address urgent problems and those that introduce innovations to improve or enhance human life:Wound healing;Regenerative tissue engineering and personalized medicine—to a large extent still experimental, expensive, and difficult to reproduce (transplantation of organs or tissues with a very high degree of biocompatibility or tissue regeneration in situ);Generation of flexible, modular, modifiable, controllable, accurate, and physiologically representative platforms for in vitro testing models;Organs-on-chips/tissue chips for pharmacokinetic, toxicological, and pharmacodynamic testing of potential new active substances;Biosensors using modified tissues for the detection of chemical or biological agents;Biohybrid robotics (biology and mechanical engineering): biohybrid android robots that move using biological muscle tissue, 3D printed flesh, skin with self-healing properties, attached to skin-ligament mimetic structures, which provide the flexibility and adhesiveness that are necessary for rendering facial expressions but also for preventing damage or detachment from the mechanical components (Figure 19) [78];Cosmetics and plastic surgery: developing materials—tissues that can best mimic the natural component—and identifying challenges in their fabrication (e.g., for skin: sterilization to avoid infection, addition of dry glands, pores, blood vessels, nerves, and fat to obtain thicker, wrinkled skin, ensuring fluent movement with the help of sophisticated actuators, addition of biosensors for quality control of the environment, and improved interactive capabilities) contribute significantly to the development of actual solutions in cosmetics (anti-aging products, corrective products) and in plastic surgery [78]. Wound healing; Wound healing; Regenerative tissue engineering and personalized medicine—to a large extent still experimental, expensive, and difficult to reproduce (transplantation of organs or tissues with a very high degree of biocompatibility or tissue regeneration in situ); Regenerative tissue engineering and personalized medicine—to a large extent still experimental, expensive, and difficult to reproduce (transplantation of organs or tissues with a very high degree of biocompatibility or tissue regeneration in situ); Generation of flexible, modular, modifiable, controllable, accurate, and physiologically representative platforms for in vitro testing models; Generation of flexible, modular, modifiable, controllable, accurate, and physiologically representative platforms for in vitro testing models; Organs-on-chips/tissue chips for pharmacokinetic, toxicological, and pharmacodynamic testing of potential new active substances; Organs-on-chips/tissue chips for pharmacokinetic, toxicological, and pharmacodynamic testing of potential new active substances; Biosensors using modified tissues for the detection of chemical or biological agents; Biosensors using modified tissues for the detection of chemical or biological agents; Biohybrid robotics (biology and mechanical engineering): biohybrid android robots that move using biological muscle tissue, 3D printed flesh, skin with self-healing properties, attached to skin-ligament mimetic structures, which provide the flexibility and adhesiveness that are necessary for rendering facial expressions but also for preventing damage or detachment from the mechanical components (Figure 19) [78]; Biohybrid robotics (biology and mechanical engineering): biohybrid android robots that move using biological muscle tissue, 3D printed flesh, skin with self-healing properties, attached to skin-ligament mimetic structures, which provide the flexibility and adhesiveness that are necessary for rendering facial expressions but also for preventing damage or detachment from the mechanical components (Figure 19) [78]; Cosmetics and plastic surgery: developing materials—tissues that can best mimic the natural component—and identifying challenges in their fabrication (e.g., for skin: sterilization to avoid infection, addition of dry glands, pores, blood vessels, nerves, and fat to obtain thicker, wrinkled skin, ensuring fluent movement with the help of sophisticated actuators, addition of biosensors for quality control of the environment, and improved interactive capabilities) contribute significantly to the development of actual solutions in cosmetics (anti-aging products, corrective products) and in plastic surgery [78]. Cosmetics and plastic surgery: developing materials—tissues that can best mimic the natural component—and identifying challenges in their fabrication (e.g., for skin: sterilization to avoid infection, addition of dry glands, pores, blood vessels, nerves, and fat to obtain thicker, wrinkled skin, ensuring fluent movement with the help of sophisticated actuators, addition of biosensors for quality control of the environment, and improved interactive capabilities) contribute significantly to the development of actual solutions in cosmetics (anti-aging products, corrective products) and in plastic surgery [78]. In tissue engineering, there are two general approaches, bottom-up and top-down, each with its own advantages and disadvantages [70]. For each application, depending on available data and resources (budget, equipment, expertise), the optimal method is selected. In the bottom-up approach, mini-component parts of the final tissue or organ (cells, micro-tissues, scaffold materials, biomolecules) are brought together and assembled to generate the complex structure. This technique relies on the self-assembly and self-organization properties of the component parts and allows for precise design from the molecular or cellular level. The advantages of this approach are that the micro-architecture and composition of the resulting tissue are very well controlled and that heterogeneous, complex structures can be created. The main disadvantage is the difficulty of scaling to larger tissue constructs [70]. An example of the bottom-up methodology is provided by Fleischer et al. [79], who used it in cardiac tissue engineering to create functional cardiac patches (Figure 20). The group assembled a modular tissue consisting of several layers with distinct structures and functions to closely mimic the morphology and functionality of the heart and to integrate the patches with the target organ. Several biopolymeric porous scaffolds were treated differently to generate the aforementioned layers. The first layer, a matrix of albumin–electrospun fibers, was laser-shaped to create microgrooves that generate aligned fragments of heart tissue capable of propagating the anisotropic electrical signal. For the second layer, the scaffold was modeled with microchannels in which endothelial cells were seeded to form closed lumens. In the last layer, cage-shaped structures incorporating poly (lactic-co-glycolic acid) microparticle systems (PLGA) and delivery vectors that release vascular endothelial growth factor (VEGF), a vascularization promoter, or dexamethasone, an anti-inflammatory agent, were modeled into the scaffold. The structure, morphology, and function of each layer were characterized, and the tissue layers were grown separately under their optimal conditions. Before transplantation, tissue layers and microparticles were integrated into an ECM-like biological adhesive to form thick 3D heart patches. Finally, the patches were transplanted into rats, and their vascularization was evaluated. Due to the simple modularity of this approach, the authors believe that, in the future, it could be used to assemble other multicellular, thick, 3D, functional tissues. The top-down approach uses a pre-existing complex material or scaffold modeled on the characteristics of the target tissue. Decellularized tissues or organs are often used, preserving the original ECM architecture and sufficient mechanical properties of the original tissue. This scaffold is repopulated with cells from the patient to restore tissue function and avoid rejection by the body. Techniques used in the top-down approach include the electrospinning technique, which produces nanofibrous matrices that mimic the fibrous structure of the ECM and provide a conductive environment for cell proliferation, and the freeze-drying technique, which generates porous matrices with a large contact surface to promote nutrient diffusion and cell infiltration. With the top-down approach, it is easier to obtain constructs that closely mimic the original tissue. Its main advantage is the use of natural scaffolds with inherent biological cues (molecular guides), while the main disadvantage is the difficulty in precisely controlling the microenvironment and integrating different types of cells and materials into the scaffold [70]. When considering the types of products that tissue engineering generates and the materials it uses, several technologies applied by this “pilot industry” can be distinguished [70], which are summarized in Table 4 below. For a better understanding of the principles and methods that characterize the main technology used in tissue engineering, namely bioprinting, we subsequently provide a detailed description. Overall, the comparative analysis of biofabrication technologies (described in Table 4) highlights that there is no universally superior method, but rather a set of complementary tools, each optimized for a certain level of structural, functional, or biological complexity. Cell-based techniques—from the use of stem cells to organoids and self-assembly—offer high biological fidelity but limited geometric control, while additive biofabrication methods, such as 3D/4D bioprinting or laser-assisted techniques, allow for precise architectures but depend on biomaterials and may affect cell viability. In parallel, scaffold processing technologies (electrospinning, decellularization, freeze-drying, TIPS/DIPS, SC/PL) offer a wide range of options for obtaining porous, layered, or biomimetic structures, but with trade-offs between microstructural control, scalability, and shape complexity. Micro- and nanofabrication, along with lithography and microfluidics, complete the landscape with the ability to create extremely precise micro-architectures, which are essential for advanced tissue models or organ-on-chip systems. The differences between the techniques become much more evident when studied side by side: for example, organoids and self-assembly more closely replicate natural cellular organization processes than 3D bioprinting, but bioprinting enables large-scale structures with controlled geometry that are impossible to achieve through self-assembly. Similarly, electrospinning generates submicron fibers similar to the extracellular matrix but cannot reproduce complex macro-architectures, such as those obtained by stereolithography or FDM. TIPS and DIPS allow fine control of porosity, but SC/PL offers larger and interconnected pores, which are useful for bone implant engineering, while gas-foaming produces porous structures without solvents, but with less uniform pore distribution. Laser-assisted bioprinting (LAB) techniques outperform conventional bioprinting in cellular resolution, but microfluidics offers superior control over the dynamic environment and biochemical gradients. The technique of removing cellular components from tissues remains superior to any other when it is necessary to preserve the native architecture of an organ but is inferior to microfabrication techniques when the reproduction of specific microstructures is required. Therefore, the choice of the optimal technique depends on the necessary balance between biological fidelity, architectural control, scalability, and the final function of the construct, emphasizing the integrative and interdisciplinary character of modern tissue engineering. Three-dimensional printing is a process that creates materials layer by layer. The process is automated, guided by CAD (computer-aided design) software, and belongs to the family of additive manufacturing technologies, in which objects are formed by adding material, in contrast to subtractive manufacturing, where material is removed by cutting, drilling, perforating, or grinding. The main difference between “additive manufacturing” and “3D printing” lies in their scale of application: the former is used at the industrial and commercial level and involves more operational processes beyond the actual manufacturing of the object, such as design, material traceability, workflow management, and quality control. The latter is applied on a small scale, at the prototype level, and is intended for individual users and start-ups, at most reaching pilot scale. The CAD software contains the digital model of the object to be printed and transmits information to the printer regarding the location and quantity of material to be deposited. Most 3D printers use polymers, but some also support metals or ceramics. The technologies used in 3D printing include fused deposition modeling (FDM), selective laser sintering (SLS), stereolithography (SLA), and PolyJet. For additive manufacturing, applicable methods include powder bed fusion (PBF), fused deposition modeling (FDM), and material jetting (MJ) [122,123,124,125]. Three-dimensional bioprinting (3DBP) is a form of 3D printing that uses biomaterials and biologically functional components, such as cells and biomolecules or signaling molecules. Printing is performed in a predefined framework, layer by layer, resulting in living tissue. Through 3DBP, microphysiological systems (MPS) are created, including organoids, organs-on-chips, tissues, and their combinations, which are used as implantable or ex vivo devices to improve function, replace lost tissues, study physiology, or test chemicals and drugs. Their use can serve therapeutic, diagnostic, or prognostic purposes. Micropathological systems (MPtSs) are MPS used to study diseases instead of normal physiology. They are biomimetic systems that accurately recapitulate the biological microenvironment [91]. Four-dimensional printing uses the same techniques as 3D printing but employs responsive materials, allowing the resulting structure to change its properties, shape, or even functions over time in response to applied stimuli. This makes it a dynamic construct, with time as the fourth dimension considered in its name [91]. Four-dimensional bioprinting involves the precise deposition of biomaterials and biologically active components into constructs that can undergo deformations and conformational or functional transformations over time when exposed to various stimuli. These constructs mimic the dynamic changes naturally found in the human body or alter their architecture to enable controlled release of encapsulated drugs, making them excellent for drug delivery. They are also ideal for bioactivation, wound healing, biosensing, and biorobotics [91,126]. Thus, 4D bioprinting produces dynamic bio-constructs that respond to stimuli and transform over time (smart), whereas 3D bioprinted structures remain static [127]. Tissue engineering applications have multiple facets that depend on each other, much like elements of an ecosystem. Scaffolds, advanced drug-delivery systems, regenerative medicine, and personalized medicine can each serve as either a component or the entire product in efforts to improve human health. As (bio)materials used in tissue engineering, polymer matrices have three general functions [89]: they act as space-filling agents, delivery vehicles for bioactive molecules, and 3D structures (scaffolds) that organize and signal cells for tissue production or cell delivery (Table 5). Within the last listed function (tissue scaffold), the matrices direct cellular behavior, tissue formation, and integration within the host organism [89]. To fulfill these roles, the scaffold (finite product) and the biomaterials composing it (biopolymers) must meet specific physical characteristics (mechanical resistance, crosslinking dynamics, porosity), physicochemical characteristics (degradation rate, surface chemistry, molecular diffusion, active molecule delivery: transport and release), and biological characteristics (biocompatibility, non-toxicity) tailored to each application or environment for which the scaffold is designed. For example, regarding mechanical properties, soft scaffolds are used for nervous and adipose tissue, while hard scaffolds are used for bone and cartilage tissue. Mechanical resistance influences mechanotransduction (the transformation of mechanical stimuli into biological signals), affecting gene expression and cell behavior. Scaffolds created for cell encapsulation must crosslink without damaging the cells, be non-toxic to both the cells and the tissue where they will be implanted, allow adequate diffusion of nutrients and metabolites to and from the encapsulated cells and surrounding tissue, and exhibit sufficient integrity and mechanical strength to withstand all manipulations necessary for implantation and in vivo operation. The degradation rate must match the rate of tissue formation to prevent collapse of the targeted tissue and to ensure proper integration and function. Peptides sensitive to specific enzymes can be incorporated to balance the durability of the scaffold’s architectural support with its degradation rate. The degradation products, like the biopolymers themselves, must be non-toxic, non-inflammatory, and easily absorbed and excreted by the body, as in the case of polylactic acid (PLA) and polyglycolic acid (PGA). The surface chemistry of biomaterials is critical because it influences protein adsorption, cell adhesion, and the medium- to long-term behavior of cells. For example, materials with binding domains such as RGD (arginine–glycine–aspartic acid) stimulate cell adhesion and, consequently, tissue regeneration. Surface modifications can be achieved by binding peptides or growth factors, which promote specific cellular activities; growth factors, in particular, should be released in a controlled manner to support natural processes of cell adhesion, growth, proliferation, and regeneration. Surface characteristics, such as topography and chemical functionality, influence the adhesion and incorporation of biomolecules (growth factors), and their optimization leads to improved cell–matrix interactions. Nanoscale scaffolds (scaffolds with nanoscale engineered surface characteristics) provide ECM-like topographic signals and have a higher surface-to-volume ratio, better supporting natural cellular behavior. In contrast, microscale scaffolds (scaffolds with microscale surface properties) better facilitate cell infiltration, nutrient diffusion, and vascularization, thus supporting tissue formation. The key to obtaining tissue that is both accurate and easily integrated is the harmonious combination of these two types of surface structures [70,77,128,129,130,131]. Many tissue engineering scaffolds initially fill a space occupied by natural tissue and then provide a framework for tissue regeneration. In this context, the physical properties of the material are essential to the success of the scaffold [77]. Examples of polymeric materials used as 3D supports (scaffolds) in tissue engineering [77,128,132]:(a)Poly(lactic-co-glycolic) acid (PLGA) is an FDA-approved copolymer for medical devices and for use inside the human body. Its main disadvantages are hydrophobicity and processing in harsh conditions, which make it difficult to incorporate living cells and growth factors into the scaffold it generates.(b)Poly glycerol-sebacate (PGS) is a polyester (biocompatible and biodegradable synthetic polymer) prepared by polycondensing glycerol with sebacic acid. It has a low synthesis cost, which makes it promising for the growing tissue engineering industry [133]. (a)Poly(lactic-co-glycolic) acid (PLGA) is an FDA-approved copolymer for medical devices and for use inside the human body. Its main disadvantages are hydrophobicity and processing in harsh conditions, which make it difficult to incorporate living cells and growth factors into the scaffold it generates. Poly(lactic-co-glycolic) acid (PLGA) is an FDA-approved copolymer for medical devices and for use inside the human body. Its main disadvantages are hydrophobicity and processing in harsh conditions, which make it difficult to incorporate living cells and growth factors into the scaffold it generates. (b)Poly glycerol-sebacate (PGS) is a polyester (biocompatible and biodegradable synthetic polymer) prepared by polycondensing glycerol with sebacic acid. It has a low synthesis cost, which makes it promising for the growing tissue engineering industry [133]. Poly glycerol-sebacate (PGS) is a polyester (biocompatible and biodegradable synthetic polymer) prepared by polycondensing glycerol with sebacic acid. It has a low synthesis cost, which makes it promising for the growing tissue engineering industry [133]. In addition, the mechanical properties and degradation kinetics of PGS can be tailored by controlling crosslinking time, crosslinking temperature, reactant concentration, and acrylate degree (in PGS acrylate) to meet application requirements. Due to the flexible and elastomeric nature of PGS, its biomedical applications are primarily focused on the replacement and engineering of soft tissues, such as heart muscle, blood vessels, nerves, cartilage, and retina. However, PGS applications have expanded to include drug delivery, tissue adhesives, hard tissue (bone) regeneration, and the design and manufacture of devices for applications that mimic native physiological conditions. New PGS scaffold designs range from honeycomb microstructures folded like an accordion to cardiac patches (PGS can generate porous, elastomeric 3D scaffolds with controllable stiffness and anisotropy; accordion-like folded honeycombs overcome the main structural and mechanical limitations of previous scaffolds, namely the inability to recapitulate cardiac anisotropy and to adjust flexibility, thus promoting the formation of aligned heart cell grafts and achieving mechanical properties more similar to native myocardium [134]), to gecko-inspired surfaces for tissue adhesives (gecko lizards can climb flexibly on a variety of natural surfaces due to the finely layered structure of their feet, which provides adhesion to any material—a structure that the scientific community has mimicked by creating dry adhesive surfaces [135], such as those based on PGS), and to PGS nanofibers for ECM-mimicking constructs [133]. (c)Hydrogels: The structural integrity of hydrogels depends on the crosslinks formed between the polymer chains, whether through chemical bonds or physical interactions. The advantages of hydrogels are that they are structurally similar to the extracellular matrix of many tissues, can be processed under gentle conditions (including physiological conditions), and can be administered in minimally invasive ways. In tissue engineering, they are used for delivering drugs and growth factors and for manufacturing tissue replacements. Hydrogels: The structural integrity of hydrogels depends on the crosslinks formed between the polymer chains, whether through chemical bonds or physical interactions. The advantages of hydrogels are that they are structurally similar to the extracellular matrix of many tissues, can be processed under gentle conditions (including physiological conditions), and can be administered in minimally invasive ways. In tissue engineering, they are used for delivering drugs and growth factors and for manufacturing tissue replacements. A drug-delivery system is like a “prepaid molecular taxi” that transports active compounds safely, protecting them from degradation and releasing them at targeted sites. This enhances their efficacy and protects the body from additional adverse reactions that would occur if the medicine were not delivered specifically to its destination tissue. These properties address the typical drawbacks of conventional formulations, which lack specific targeting mechanisms and rely solely on the drug’s properties and its biodistribution process. For example, chemotherapeutic agents are highly toxic to every cell in the body, not just the tumor, and are generally small-molecule drugs that are rapidly cleared from circulation, making it difficult to maintain a therapeutic concentration at the site of action [136]. Overall, drug-delivery systems (DDS) have two major objectives, with two consequential effects: spatial and temporal control of drug delivery to maximize efficacy and minimize adverse reactions. Optimal dosing, controlled drug release, prolonged systemic circulation, and low toxicity are four characteristics of a successful drug-delivery system [137]. The controlled timing and location of drug release are achieved by modifying the drug’s kinetic and dynamic properties through the DDS formulation process, resulting in a more effective and safer outcome [136]. Drug-delivery systems (DDS) and tissue engineering (TE) are two interconnected fields. TE technologies can be used to tailor DDS by building scaffolds or multilayered constructs for controlled release, or by printing the entire system with encapsulated therapeutic agents. Meanwhile, DDS principles improve the results of TE products (scaffolds, tissues, or organs) by transforming them into platforms that respond to the environment and release growth factors, antibiotics, and other bioactive molecules that help the artificial construct integrate better into the body or serve a dual function: prosthetic (replacement) and therapeutic (antitumoral, regenerative, healing, anti-inflammatory, and so on). In tissue engineering, the sustained, extended, and controlled release of active principles, signaling molecules, or growth factors is generally preferred, as these approaches can accelerate the regenerative process by maintaining a constant concentration of the desired molecule at the affected site over an extended period. They can also provide a timed release that aligns with the phases of cellular differentiation or stages of wound healing, while minimizing potential undesired systemic effects. The main concern and challenge is achieving an optimal balance between the release rate and the structural properties of the scaffold, which should not degrade before the new tissue has stabilized. Additionally, release patterns vary depending on the type of tissue: soft or hard. In soft tissues (such as liver, renal, cutaneous, skin, ocular, and others), high vascularization leads to rapid drug absorption and clearance, necessitating sustained or extended release. In contrast, hard tissues (bones, teeth) require controlled and/or localized (targeted) release to support processes like bone regeneration. Controlled release often employs nanoparticles or scaffolds to rapidly achieve an initial therapeutic concentration, followed by sustained release to maintain plasma concentration [136]. As previously mentioned, controlled release can also refer to targeted release [138], based on specific molecular interactions such as ligand-receptor binding, or to stimuli-based release (mechanical, pH, temperature, light, etc.), which can be achieved if the drug vehicle is formulated with a stimuli-responsive biomaterial. Controlled release considers both timing and location. In different contexts, it refers to drugs released over a specific period to ensure constant plasma concentrations, drugs released at a particular moment, or drugs released at a specific site identified by surface or immunological interactions—such as ligand–receptor biochemical bonds, antibody–antigen bonds (active targeting), or the enhanced permeability and retention (EPR) effect in tumors (passive targeting). These strategies enhance drug accumulation at the target site and improve therapeutic efficacy while reducing systemic side effects [136]. Targeted drug delivery, or smart drug delivery, refers to formulations that direct active substances to accumulate at desired locations in the body, primarily represented by nanomedicine. Nanotechnology has paved the way for developing new drug vehicles capable of transporting a wider variety of substances and delivering them with greater specificity and controlled release patterns [139]. Drug-delivery systems can be (A) hydrogel-based, (B) scaffold-based, (C) nanoparticle-based, or (D) cell-based, and they can also be completely natural, synthetic, or have elements from both areas. i.Hydrogel-based DDS Hydrogel-based DDS One essential criterion affecting the capacity of polymeric materials (e.g., natural: cellulose, chitosan, hyaluronic acid (HA); synthetic: polycaprolactone (PCL), poly(lactic-co-glycolic acid) (PLGA)) to function as scaffolds in drug-delivery systems (DDS) is the drug’s release rate, which depends on their degradation mechanisms. Combining a polymer with a lipid improves the stability and controlled release of the delivery system [139]. Biodegradable polymers are promising gene delivery vehicles because they do not accumulate and have no toxic effects on targeted cells and tissues. Hydrogel-based dressings can deliver antibiotics and growth factors to enhance wound healing, and injectable hydrogels can deliver growth factors and cells to improve cardiac function. ii.Scaffold-based DDS Scaffold-based DDS Collagen-based scaffolds can deliver drugs, proteins, and genes. For example, Collatamp®-G is a collagen-based gentamicin delivery vehicle that provides sustained local delivery of antibiotics. Septocoll® offers prolonged delivery by incorporating two gentamicin salts with different solubility rates. Collagraft® is a biodegradable synthetic bone graft formulated as a composite of a collagen matrix and biphasic calcium phosphate. PerioCol®-CG and GDT PerioFocus are biodegradable chlorhexidine chips used in periodontics to provide sustained local delivery of the antimicrobial substance. The main drawback of collagen-based scaffolds is the immunogenic reaction to antigenic sites in the natural collagen molecule. Other disadvantages include the risk of infection when collagen is collected from xenogeneic sources and the degradation properties of the scaffolds. Genetically engineered collagen from Escherichia coli or yeast could address these problems, but this must become an industrially feasible solution. Hyaluronic acid (HA) is known for its ability to promote wound healing through mesenchymal cell differentiation and its attachment to various cell receptors. Scaffolds made from this molecule can be used to deliver anti-inflammatory and antitumor drugs in a controlled and targeted manner. Similarly, chitosan-based scaffolds are frequently used in the development of wound-healing, controlled-release applications due to the natural antimicrobial properties of the molecule. Hyaluronic acid and chitosan are also cationic molecules, so the release of substances included in their matrices can be pH-dependent. Preclinical studies showed that hydroxyapatite-based 3D-printed scaffolds can deliver growth factors such as bone morphogenic protein (BMP) or platelet-rich plasma (PRP) and enhance bone regeneration. The same effect was observed with a hydroxyapatite/chitosan scaffold doped with bone marrow mesenchymal stem cells (BMSCs). Synthetic polymers can also serve as starting points for drug vehicles that offer modified release, with advantages such as easier processing, improved mechanical properties, and customizable pore sizes and geometries of the fabricated scaffolds. For example, polycaprolactone (PCL) scaffolds have slow degradation rates, while polylactic acid (PLLA) and polylactic-co-glycolic acid (PLGA) degrade quickly. These two types of scaffolds are sometimes combined in different proportions to modulate the erosion rate or achieve a two-phase release profile (immediate release and sustained release). PLGA scaffolds are effective in delivering vaccines, antibiotics, and anti-inflammatory drugs due to their rapid degradation [139]. iii.Nanoparticle-based DDS Nanoparticle-based DDS Nanomedicines are pharmaceutical agents that use nanoscale materials (1–200 nm) to deliver therapeutic small-molecule drugs to the site of action through targeted, smart, or controlled drug delivery. Nanomaterials enter cells via endocytosis, usually mediated by cell-surface receptors. Nanomaterials are typically positively charged and are therefore easily attracted to cells, which are negatively charged. Because endocytosis is mediated by lysosomes, nanomaterials must be resistant to low pH and lysosomal activity [137]. Polymeric nanoparticles (NPs) can be produced using techniques such as emulsification, ionic gelation, and nanoprecipitation from natural or synthetic materials and can take two forms: polymerosomes and micelles. Drugs can be encapsulated within the nanoparticle core, chemically conjugated to the polymer, or simply bound to the particle surface. The composition and surface charge of the particles determine the efficacy of drug loading and release [139]. Polymerosomes are artificial vesicles with membranes made of amphiphilic copolymers, offering excellent stability and cargo-retention efficiency, which are highly desirable for drug-delivery systems (DDS). They can also function as nanoreactors, protecting enzymes or proteins in nanometer-sized compartments and preserving their in situ functionality. Polymeric micelles are composed of amphiphilic copolymers with a hydrophobic core and a hydrophilic shell, making them ideal for transporting hydrophobic drugs through aqueous environments. Their production involves dissolving the polymer in a solvent, followed by dialysis or precipitation using another solvent. Direct dissolution, solvent evaporation, and dialysis are methods for introducing drugs into polymeric micelles [139]. Both types of polymeric nanoparticles can have their surfaces modified or functionalized to enhance targeting capabilities and optimize bioavailability; however, their main drawbacks are the risk of particle aggregation and associated toxicity [139]. NPs constitute a significant portion of clinically approved nanomedicines due to their biocompatibility, stability, biodegradability, and multifunctionality, as well as their utility in targeted and controlled drug delivery. Examples of polymeric nanoparticles used in cancer therapy include Oncaspar (Asparaginase), a polymeric conjugate used in acute lymphoblastic leukemia; Eligard (Leuprolide acetate), a polymeric matrix used in advanced prostate cancer; Nanoxel (PTX), polymeric nanoparticles used in breast cancer, pancreatic cancer, and NSCLC; and Docetaxel PM (Docetaxel), polymeric micelles used in breast cancer, gastric cancer, NSCLC, ovarian cancer, prostate cancer, and squamous cell cancer [140]. Targeting specific sites of action can be achieved either passively or actively. Passive targeting involves coating the nanoparticle with a macromolecule that attracts water molecules through hydrogen bonding (PEG is often used), making the particle hydrophilic. As a result, the reticuloendothelial system (RES) does not process the nanoparticle (rendering it antiphagocytic), which extends its circulation time and allows it to diffuse into the desired tissues. Active targeting provides greater specificity through ligand–receptor or antigen–antibody binding. In cancer treatment, active tumor targeting involves functionalizing nanoparticles to recognize and bind to tumor-associated markers, while tumor-selective activation uses stimuli-responsive materials that release the active substance in response to internal signals from the local microenvironment (such as pH, oxygen levels, enzymatic activity, and redox potential) or external stimuli (such as phototherapy, ultrasound, or irradiation). The multiple tumor-targeted strategy combines active tumor targeting and tumor-selective activation to enhance therapeutic efficacy and minimize adverse reactions [140]. In terms of applications, nanoparticle-based drug-delivery systems are highly useful in combination with tissue engineering, for example, in treating bone cancer, trauma injuries, osteoporosis, and amputations. Ceramic nanoparticles made of PLGA, gelatin, collagen, and chitosan are most commonly used for bone regeneration. Bisphosphonate drugs, some of which promote osteoblast activity and others that decrease osteoclast activity, can combine with regenerating nanoparticles and bone minerals to treat osteoporosis [73]. Polymeric nanovehicles can also improve the efficacy of statin therapy [73]. iv.Cell-based DDS Cell-based DDS Immunotherapy is a branch of the biomedical field in which drug-delivery systems (DDS) hold significant potential. There have been efforts to use DDS to initiate an immune response by introducing immune checkpoint inhibitors into the body [139]. Immune checkpoint inhibitors are monoclonal antibodies used in cancer therapy. Immune checkpoints are partner proteins located on immune cells, such as T cells, and on cancer cells, which recognize each other and prevent immune cells from killing tumor cells. This occurs because the proteins on cancer cells are the same as those on healthy cells, preventing the immune system from attacking the body’s own tissues. Immune checkpoint inhibitors block either the T cell receptors or the proteins on cancer cells that bind to these T cell receptors, thereby boosting the immune system to kill cancer cells. They have been used to treat lung cancer, breast cancer, bladder cancer, cervical cancer, colon cancer, head and neck cancer, Hodgkin lymphoma, liver cancer, renal cell cancer, skin cancer including melanoma, stomach cancer, rectal cancer, and any solid tumor that cannot repair DNA errors occurring during genetic material replication [141,142,143]. However, the risk of rapid clearance caused by immunogenic reactions to the materials used in DDS fabrication and concerns about long-term toxicity remain limitations, prompting the search for better solutions. The most promising alternative is the use of endogenous cells themselves, as they are natural vehicles for biomolecules in the body, transporting proteins, enzymes, and nutrients. Toxicity, immunogenicity, biological barriers, biocompatibility, and targeted delivery are much less significant or even nonexistent risks for cell-based drug-delivery systems. These characteristics make them ideal for antiviral and antitumoral therapy (e.g., leukemia, ovarian cancer). Red blood cells (RBCs), neutrophils, and dendritic cells (DCs) are cell types used in cell-based delivery technology [139]. RBCs are advantageous as drug carriers for several reasons: they lack nuclei, providing ample space for drug encapsulation; they circulate throughout the entire body; they have a long half-life (115 days) compared to most other blood cells—platelets (10 days), monocytes (3 days), reticulocytes (2 days), basophils (1–2 days), eosinophils (0.5 days), neutrophils (0.3 days); they are by far the most abundant [144], as shown in Figure 21; and they offer a large surface area for drug assembly. Additionally, the presence of surface markers such as CD47 protects them from phagocytosis. A challenge in using RBCs as drug vehicles is that surface conjugation of drugs reduces their elasticity and deformability, making them more susceptible to accelerated clearance by the reticuloendothelial system [139]. Neutrophils are blood cells that are chemoattracted to sites of inflammation, especially those caused by pathogen invasion, so their natural pathway can be very useful for drug delivery of anti-inflammatory or antimicrobial agents. Drugs are conjugated to their surface or internalized through co-culture methods [139]. Dendritic cells present antigens to T cells and secrete cytokines to promote T cell accumulation and enhance the killing activity against pathogens. Based on their natural functions, dendritic cells are used as cell-based drug-delivery systems to deliver antigens and activate the immune system in cancer [139]. i.DDS interaction with scaffolds DDS interaction with scaffolds In tissue engineering, scaffolds serve two main purposes: (1) providing temporary support structures that facilitate cellular growth and organization, and (2) acting as vehicles for cells, drugs, and genes [136]. Responsive and autonomous biomaterials are extremely useful for developing controlled-release drug-delivery systems or scaffolds with this function. However, many scaffolds, especially porous ones, deliver biological agents primarily through passive mechanisms such as molecular diffusion, material degradation, and cell migration, rather than through active, dynamically regulated (stimuli-based) processes. The bioactive substances or therapeutic cells loaded into the scaffolds have a specific dispersion pattern (either even or discrete distribution), which must not disrupt the scaffold structure, and their release must ensure effective treatment over the desired period throughout the entire targeted area [136]. ii.DDS interaction with the extracellular matrix (ECM) DDS interaction with the extracellular matrix (ECM) As with most components of living cells, the extracellular matrix (ECM) is a double-edged sword: on one hand, its mesh-like structure limits the penetration and distribution of active substances to their targets; on the other hand, it serves as a pool of targeting sites that can be used to facilitate drug delivery. One example of this adjuvant role is seen in the interaction between integrins, a family of cell surface receptors, and the ECM proteins to which they bind. Targeting integrins with ligands (drugs) can enhance drug delivery into the cell, a strategy that has been successfully applied in cancer treatment [136]. ECM-degrading enzymes, such as matrix metalloproteinases (MMPs) that cleave specific ECM proteins, represent a second way to improve drug absorption at the desired site. This has been achieved using liposomes loaded with such enzymes, also for tumors. Biomimetic materials, such as hydrogels made of ECM proteins or glycosaminoglycans that mimic the structures and properties of the ECM, are used as drug-delivery systems, especially in wound healing, tissue engineering, and cancer treatment [136]. iii.DDS interaction with cells DDS interaction with cells Cell-mediated drug delivery is particularly attractive for its therapeutic specificity and effectiveness, as other drug-delivery systems still face challenges in this area, despite the development of several surface markers and targeting approaches [136]. In cell-based drug-delivery systems, the therapeutic agent can be encapsulated within the cell, attached to the cell surface, or secreted in a controlled manner by a genetically engineered cell. Therapeutic gene networks are now used to develop highly advanced sensory and output devices, which will change how patients receive their medicine, especially those with chronic diseases [136]. Although preclinical studies present nanomedicine as very promising for tumor therapy due to improved pharmacology and toxicology of drugs [145], physiological barriers prevent nano-carried drugs from reaching their site of action in clinical studies, rendering them inefficient. In contrast, cell-mediated drug delivery offers high targeting efficiency and strong specificity; cells easily surpass various biological barriers, exhibit low immunogenicity, and have long circulation times in the bloodstream [136]. Therefore, combining nanomedicine and cell-based drug-delivery systems addresses the limitations of each approach. For skin applications, various tissue engineering products have been developed as drug-delivery systems, such as patches, injectable devices, and subcutaneous implants, many of which focus on wound healing, prevention of inflammatory processes, and burn treatment [136]. To increase nanoparticle penetration through tissues, PEG- (muco-inert) and TAT-peptide- (cell permeation enhancer) coated nanoparticles were developed, which demonstrated improved traversal of artificial cystic fibrosis mucus and lung epithelial cells [136]. Regenerative and personalized medicine focus on creating tissues, organs, and medicines that are perfectly adapted or tailored to the recipient. Regenerative medicine involves replacing or regenerating cells, tissues, or organs in the human body to restore their normal function. This branch of medicine includes methods such as cell therapy, gene therapy, tissue engineering, and biomedical engineering techniques, as well as more traditional treatments involving pharmaceuticals, biologics, and medical devices. It has enormous potential to cure diseases, improve quality of life, and generate significant economic benefits [146]. The common methods used to create products for application in regenerative medicine are:Generating a scaffold to guide the architecture of the new tissue;Activation of cells capable of initiating and sustaining regeneration with the help of growth factors (or genetic reprogramming factors);Combining the two methods, in consecutive or simultaneous steps. Generating a scaffold to guide the architecture of the new tissue; Generating a scaffold to guide the architecture of the new tissue; Activation of cells capable of initiating and sustaining regeneration with the help of growth factors (or genetic reprogramming factors); Activation of cells capable of initiating and sustaining regeneration with the help of growth factors (or genetic reprogramming factors); Combining the two methods, in consecutive or simultaneous steps. Combining the two methods, in consecutive or simultaneous steps. Personalized medicine is an emerging medical field that uses an individual’s genetic profile to guide decisions about the prevention, diagnosis, and treatment of their disease. In cell-based therapy and in cell-based plus smart biomaterial scaffold therapy, tissue engineering has made significant progress in recent decades, with widespread applications across most biological systems. For the skin, autologous skin substitutes have been developed, including bioengineered bilayered grafts that effectively cover wounds, stimulate regeneration, and reduce scar formation [73,74,75]. Products such as Apligraf and Dermagraft—the latter combining dermal tissue with an artificial epithelium—are already integrated into therapeutic protocols for burns and diabetic foot ulcers [73,74,75]. In parallel, 3D bioprinting enables the controlled deposition of cells and biomaterials, generating layered structures that closely reproduce the complexity of skin [70]. In the skeletal system and associated connective tissues, mesenchymal stem cells (MSCs) have become central to personalized orthopedic therapies, being used to treat fractures, bone defects, and osteoporosis, as well as in the development of bone and dental implants [70,73,75]. Tissue engineering has also enabled the regeneration of cartilage tissue, including the reconstruction of auricular cartilage and laryngeal tissue [73,75]. In the cardiovascular field, vascular grafts have been produced by 3D bioprinting or by concentric wrapping of vascular cells and fibroblasts on biodegradable tubular supports, which are then seeded with endothelial cells, without the use of synthetic materials [74]. Capillaries and cardiac patches based on fibrin or synthetic polymers such as PGS have also been created and used for the regeneration of post-infarction myocardium, with promising clinical results in reducing morbidity and mortality [70,73]. The functional maturation of these constructs is accelerated by electrical stimulation [70]. For endocrine diseases, functional thyroid structures capable of producing thyroid hormones have been obtained [74]. At the hepatic level, current therapies target both hepatic steatosis and the associated muscle atrophy [73]. Liver spheroids generated by combining polyurethane foam with hepatocyte cultures are also used in preclinical drug testing [74]. Bioprinting enables the fabrication of liver tissue with controlled architecture and the integration of a functional vascular network, using hepatocytes or stem cells [70]. In the visual system, tissue engineering has produced innovative therapies for glaucoma [73] and for limbal stem cell deficiency (LSCD), a condition characterized by the inability of the cornea to regenerate. Current strategies include autologous corneal epithelial cell culture (CACE), simple limbal epithelial transplantation (SLET), and the use of hydrogel or plasma-based contact lenses for in vivo culture of transplanted cells, techniques that are at various stages of preclinical and clinical validation [73,147]. For nervous tissue, therapies for peripheral nerve and spinal cord injuries have been developed based on scaffolds made from polymers such as PLGA and chitosan. These facilitate axonal guidance and support neuronal adhesion, combined with growth factors and neural or mesenchymal stem cells capable of differentiating into neurons and glial cells [70]. Smart biomaterials have also produced notable results in other systems, such as the respiratory system, where lung tissue substitutes are used in radiofrequency tumor ablation therapy, improving efficacy and reducing toxicity [73]. In the skeletal system, biodegradable scaffolds such as Pro-Osteon—a coral-derived graft—and composite polymer scaffolds offer effective solutions for fractures and bone defects, with extended lifespan and superior integration in orthopedic applications [74]. Overall, recent advances in tissue engineering and biomaterials demonstrate considerable potential for the development of personalized regenerative therapies capable of reproducing the structure and function of native tissues, thus contributing to the transformation of therapeutic paradigms in modern medicine. 5. Market View, Challenges, and Perspectives The global biomaterials market is projected to reach USD 442 billion by 2035, with an expected annual growth rate of 7.9%, starting from USD 193 billion in 2019 [148]. This projection is supported by the increasing prevalence of chronic diseases and an aging population [2,149,150,151]. Personalized and regenerative medicine, along with advanced drug-delivery systems in the pharmaceutical sector, address the needs arising from these circumstances. As a result, more funding and greater effort are being invested in biomaterials [148], which are key elements in these healthcare sectors. Despite this progress, there remains a gap in the bench-to-bedside translation of biomaterial-based products, tissue-engineered products, and individually tailored medicines, as well as in achieving the desired long-term stability and integration of biomaterials in the human body [148]. The development of increasingly advanced nano- and micro-fabrication technologies for biomaterial manipulation and customization is making these materials more versatile and effective. The growing number of start-ups and spin-offs (research-oriented start-ups) and the increasing trust they receive from both investors and the public are also positive factors in the effort to improve biomaterials’ properties and deliver innovative healthcare solutions more quickly to patients. These micro-companies focus on rapid growth and fast solutions to specific market needs, and they have a much shorter timeline from minimal viable product (MVP) to final product and actual sales compared to large, industrial, multinational companies. However, they usually operate at the pilot level rather than on an industrial scale, making them less procedural, faster, and more flexible—qualities that the biomedical field needs to accelerate the production and marketing of innovation-based solutions. Additionally, spin-offs are typically launched by academic research groups, so the team’s expertise is central to the company, which greatly benefits the research and development process. Once a spin-off has demonstrated market viability, it is usually acquired by a large-scale production company, allowing its products to be scaled up in mass production, quality management systems, automated production processes, and even applications. Although biomaterials include metallic, ceramic, polymeric (natural or synthetic), and emerging materials, natural and emerging materials are currently trending [148] due to their increased biocompatibility and advanced functionalities. The biomaterial industry has various application areas: cardiovascular (guidewires, implantable cardiac defibrillators, pacemakers, sensors, stents, vascular grafts, and others), ophthalmology (contact lenses, intraocular lenses, ocular tissue replacements, synthetic corneas, and so on), dental (bone grafts and substitutes, dental implants, dental membranes, tissue regeneration materials), orthopedic (bioresorbable tissue fixation products, joint replacement biomaterials, orthobiologics, spine biomaterials, visco-supplementation), wound healing (adhesion barriers, internal tissue sealants, skin substitutes, surgical hemostats, fracture healing devices), plastic surgery (acellular dermal matrices, bioengineered skin, soft tissue fillers, peripheral nerve repairs), neurology (cortical neural prosthetics, shunting systems, hydrogel scaffolds for central nervous system repair, neural stem cell encapsulations), and many others. Currently, the wound healing, plastic surgery, orthopedic, dental, and cardiovascular segments lead in market share by application area [148]. Companies manufacturing biomaterials-based products include BASF SE, Berkeley Advanced Biomaterials, Carpenter Technology, Collagen Matrix, CoorsTek, Corbion, Covalon Technologies, CRS Holdings, Dentsply Sirona, Evonik Industries, Invibio, Johnson and Johnson, Medtronic, Stryker, and Zimmer Biomet [148]. Major tissue engineering companies include AbbVie Inc., Acell Inc., Acelity L.P. Inc., Athersys Inc., Baxter International Inc., Becton Dickinson and Company, BioMed X, B. Braun, Cytori Therapeutics, Episkin, Integra LifeSciences Corporation, Medtronic plc, Organogenesis Inc., Osiris Therapeutics, ReproCell Inc., RTI Surgical Inc., Smith and Nephew, Stryker Corporation, Tissue Regenix Group, Vericel Corporation, and Zimmer Biomet Holdings Inc [150,152,153]. As observed, some biomaterial-focused companies are also active in tissue engineering. These companies pursue strategic collaborations, acquisitions, mergers, and product launches to secure a larger market share. For example, in March 2024, HVD Life Science partnered with Poietis to distribute Poietis’ NGB-R platform in Australia and Germany; in July 2024, PacBio partnered with Novogene to advance genomic research, including rare diseases and oncology, which benefit the tissue engineering domain; in January 2023, BioMed X and AbbVie extended their research partnership to focus on immunology and tissue engineering after an initial joint project on Alzheimer’s disease; and in May 2023, Canon acquired cell manufacturer Kyoto Seisakusho to enter the tissue engineering market [153]. The tissue engineering market is undergoing continuous transformation, driven by the development of next-generation biomaterials and scaffolds, technological advancements (such as stem cell technology, gene editing techniques, 3D-4D bioprinting, organs-on-a-chip, and microfluidics), as well as growing applications in various medical fields and increased funding from governments and private entities [153]. The tissue engineering market size is projected to reach unprecedented levels, not only due to technological advances and lower production costs, but also because the need for organ transplantation and solutions for chronic diseases is increasing. The global tissue engineering market size was estimated at USD 19.36 billion in 2024 and is anticipated to reach USD 43.13 billion by 2030, growing at a compound annual growth rate of 14.3% from 2025 to 2030 [153]. North America dominated the tissue engineering market with a share of 51.4% in 2024, followed by Europe, due to its advanced healthcare infrastructures and research facilities. However, Asia–Pacific was the fastest-growing market, supported by a well-funded healthcare system and government initiatives [150,152,153]. In terms of applications, the orthopedics, musculoskeletal, and spine segment generated the most revenue in 2024. The end users in the biomaterials market include medical device manufacturers, pharmaceutical companies, healthcare providers (hospitals and clinics, including dental clinics), research centers, and universities [148]. All of these are expected to use biomaterials more intensively as research advances and greater focus is placed on minimizing adverse effects, providing tailored biomedical solutions for patients, and creating sustainable products, which is also a target of the 2030 United Nations Agenda for Sustainable Development [154]. To translate a biomaterial into a final biomedical product, several elements are required. Some of these are research-based, such as fabrication technologies or formulation principles, while others are regulatory-based, including quality management systems (GMP, GLP), as well as preclinical, clinical, and post-market studies. The regulatory elements remain the most time-consuming and costly, as research input is advancing more rapidly through collaborations among academia, industry, and research centers, as well as through open science publications and events. The translation process is undoubtedly a multidisciplinary journey, where commitment, agility, problem-solving, communication, innovation, and perseverance are essential for success. The effort to translate early-stage concepts into commercial products for clinical use is entrepreneurial in nature and requires a dedicated team of scientists, economists, legal, marketing, regulatory, and clinical affairs specialists driven by this specific goal. Finance and regulatory considerations need to be integrated into the product development strategy as early as possible, preferably from the beginning of the project, to ensure the process becomes a medical, research, and business success [155]. Although there are many financial, regulatory, intellectual property, and ethical challenges involved, the translation of laboratory discoveries into clinical therapies and marketable products is best achieved through strategic collaboration among academic institutions, research organizations, biotech companies, and even government bodies [148,150,152]. The real challenges encountered in the translation process lie in the market perspective, and scientists are not yet trained to think this way when studying or developing a new idea. The value proposition (what the product uniquely brings to the market, and what unsolved problem it addresses) and the associated business model (who buys and why) [155] are probably the first major milestones in bringing a product from the lab to the market. Many start-ups pivot their ideas when trying to answer these questions because they realize that the need they address is not necessarily well defined. Market studies and feedback on early MVPs help significantly with this process, and the sooner they are conducted, the more cost-efficient and time-efficient the process becomes. Next is the issue of profitability, and in many cases, the product can address more than one medical problem [155]. If the development team succeeds in identifying all the applications and benefits of their invention for all stakeholders involved (patients: different treatable conditions, different ages; caregivers: physicians, nurses, family members; governments: if the product could be reimbursed by a National Health Program), the product becomes more versatile and, as a result, has more potential buyers. In many cases, especially with innovations in the biomedical field, the regulatory environment must be adapted or changed [155], which requires substantial justification. Solid communication among researchers conducting pre-clinical and clinical tests, legal advisors, and auditors from regulatory national agencies is absolutely crucial. Even identifying the category in which the product falls (medical device, combination device, drug, biological product, cosmetic product) [156] can be a hurdle, and even when this is achieved, several factors must be considered for the tests and trials required for commercialization. Additionally, regulations differ from state to state, representing another challenge. Aligning requirements at the continental or even global level would greatly facilitate the translation process and help patients worldwide. Especially for orphan drugs or devices for unaddressed medical problems, it is advisable to start a conversation with international consortia, NGOs, and research societies, as they have contacts, databases, case studies, and generally more resources that, when combined, can build a stronger case or clarify whether the direction of such an effort is justified. Nonetheless, the energy of the families of potential beneficiaries of biomaterial-based products, as well as other innovative medical products, is immense, and these stakeholders have the power to influence decision-makers regarding the speed of the regulatory process or the financing of such projects. 6. Conclusions Biomaterials are undergoing rapid integration in the biomedical field, where they are urgently needed to address medical conditions that place a significant burden on patients, their families, and healthcare systems (including caregivers, institutions, and governments). Among the problems they address, the most prevalent are chronic diseases (cardiovascular, orthopedic, dental, neurological, diabetes), traumatic injuries (burns, open wounds), the need for organs or tissues for transplantation, devices that better integrate into the body and are less prone to rejection, and medicines with fewer adverse reactions, improved patient compliance, and controlled, targeted release (such as in oncology). Biomaterials are versatile materials that, depending on their generation, exhibit properties such as biocompatibility, injectability, responsiveness to stimuli, and autonomy (self-calibration). Moreover, they can be functionalized and tailored in various ways, making them suitable for diagnostic, therapeutic, and theragnostic tools (devices and medicines). Their applications range from biosensors for wearable devices or bio-robotics to smart wound dressings, advanced drug-delivery systems (nanocarriers, scaffolds, hydrogels), and tissue engineering (artificial organs, organs-on-a-chip, tissue patches, surgical adhesives). Not surprisingly, the market share for biomaterials has been growing in recent years and is expected to continue increasing significantly over the next decade, with many companies and governments investing in their research. Advancements in tissue engineering technologies and cost reductions are helping to create more feasible products more quickly and on a larger scale. The deeper incorporation of personalized and regenerative medicine into medical practice is accelerating the integration of biomaterials into everyday clinical settings. Increased collaboration between academia, industry, and research centers, with a focus on business outcomes, facilitates a multidisciplinary approach to the creation and commercialization of these innovations, accelerating production, quality control, regulatory processes, and marketing. Although the translation process from bench to bedside is not simple, more spin-offs and strategic mergers between spin-offs and multinational pharmaceutical or biomedical companies are occurring, and the gap between an idea and a final product is narrowing through shared work styles, expertise, accreditations, and resources.